Aurinia Pharmaceuticals Announces Launch of Lupus Nephritis Disease-State Awareness Initiative for Healthcare Professionals, TimeIsNephrons.com Biotech Investing
Algernon Pharmaceuticals Announces 25% Enrollment in its Ifenprodil IPF and Chronic Cough Phase 2 Human Study Biotech Investing
Eyenovia to Host Investor Call to Discuss Recent Licensing Agreements Resulting in Total Potential License Payments and Development Cost Reimbursement and Savings of Approximately $100 Million Medical Device Investing
Phase 2b/3 Trial Shows Efficacy of Filgotinib for the Induction and Maintenance of Remission in Moderately and Severely Active Ulcerative Colitis Biotech Investing
Abbott Receives FDA Emergency Use Authorization for its COVID-19 IgM Antibody Blood Test Medical Device Investing
Bausch Health Licenses Eyenovia's Investigational Treatment For The Reduction Of Pediatric Myopia Progression In Children Ages 3-12 Medical Device Investing
Bristol Myers Squibb Presents Positive Late-Breaking Data from Phase 3 True North Trial Evaluating Zeposia in Adult Patients with Moderate to Severe Ulcerative Colitis Biotech Investing
Allergan Aesthetics To Present Data From 4 Abstracts At The 2020 American Society For Dermatologic Surgery Virtual Meeting Biotech Investing
Algernon Pharmaceuticals Appoints Dr. Mark Swaim MD, PhD to its Medical and Scientific Advisory Board Biotech Investing
